ALKS•Alkermes’ third-quarter 2026 GAAP net income fell 80% year over year to $16.3 million, while revenue rose 22% to $480.1 million. The company reiterated its 2026 financial expectations.
Alkermes reported third-quarter 2026 GAAP net income of $16.3 million, down 80% year over year, and revenue of $480.1 million, up 22%. The company reiterated its 2026 financial expectations.
Alkermes said its orexin programs delivered clinical proof-of-concept data in ADHD and entered a phase 2 study in major depressive disorder.
